Una guía actualizada de diagnóstico y tratamiento | 22 SEP 20

Carcinoma cutáneo facial de células escamosas

Panorama general de los cánceres de piel. Diagnóstico y tratamiento del carcinoma cutáneo de células escamosas facial.
22
10
Autor/a: Arif M Aslam, Anand N Patel BMJ 2016;352:i1513. Facial cutaneous squamous cell carcinoma
INDICE:  1. Página 1 | 2. Referencias
Referencias

1 Diffey BL, Langtry JAA. Skin cancer incidence and the ageing population. Br J Dermatol 2005;153:679-80. doi:10.1111/j.1365-2133.2005.06799.x pmid:16120172. 2 Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166:1069-80. doi:10.1111/j.1365-2133. 2012.10830.x pmid:22251204.
3 Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001;344:975-83. doi:10.1056/NEJM200103293441306 pmid:11274625.
4 Motley RJ, Preston PW, Lawrence CM. Multi-professional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma . British Association of Dermatology (BAD), 2009.
5 Robsahm TE, Helsing P, Veierød MB. Cutaneous squamous cell carcinoma in Norway 1963-2011: increasing incidence and stable mortality. Cancer Med 2015;4:472-80. doi: 10.1002/cam4.404 pmid:25620456.
6 Green A, Battistutta D, Hart V, Leslie D, Weedon D. The Nambour Study Group. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. Am J Epidemiol 1996;144:1034-40. doi:10.1093/oxfordjournals.aje.a008875 pmid:8942434.
7 Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol 1995;22:853-7. doi:10.1111/j.1346-8138.1995.tb03935.x pmid:8557858.
8 Hacker SM, Flowers FP. Squamous cell carcinoma of the skin. Will heightened awareness of risk factors slow its increase?Postgrad Med 1993;93:115-21, 125-6.pmid:8389446.
9 Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011;65:253-61, quiz 262. doi:10.1016/j.jaad.2010.11.062 pmid:21763561.
10 Mehrany K, Weenig RH, Lee KK, Pittelkow MR, Otley CC. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 2005;53:1067-71.doi:10.1016/j.jaad.2005.08.055 pmid:16310071.
11 Lehmann AR, McGibbon D, Stefanini M. Xeroderma pigmentosum. Orphanet J Rare Dis 2011;6:70. doi:10.1186/1750-1172-6-70 pmid:22044607.
12 Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012;31:694-9. doi:10.1016/j.healun.2012.02.033 pmid:22484291.
13 Anforth R, Menzies A, Byth K, et al. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. J Am Acad Dermatol2015;72:809-15.e1. doi:10.1016/j.jaad.2015.01.018 pmid:25748298.
14 de Berker D, McGregor JM, Hughes BR. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-30. doi:10.1111/j.1365-2133.2006.07692.x pmid:17223860.
15 Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1:795-7. doi:10.1016/S0140-6736(88)91658-3 pmid:2895318.
16 Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523-30. doi:10.1002/cncr.24284 pmid:19382202.
17 Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones?Eur J Dermatol 2006;16:335-9.pmid:16935787.
18 Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007;33:1099-101.pmid:17760601.
19 Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005;53:253-60. doi:10.1016/j.jaad.2005.02.059 pmid: 16021120.
20 English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 1998;76:628-34.doi:10.1002/(SICI)1097-0215(19980529)76:5<628::AID-IJC3>3.0.CO;2-S pmid:9610717.
21 Edge SB, Byrd DR, Compton CC, et al, eds. Cutaneous squamous cell carcinoma and other cutaneous carcinomas. In: AJCC cancer staging manual . 7th ed. Springer, 2010: 301-14.BMJ 2016;352:i1513 doi: 10.1136/bmj.i1513 (Published 31 March 2016) Page 3 of 9
22 National Comprehensive Cancer Network. NCCN guidelines version 01.2012 basal cell and squamous cell skin cancers. 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
23 Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26:976-90. doi:10.1016/0190-9622(92) 70144-5 pmid:1607418.
24 National Institute for Health and Care Excellence. Guidance on cancer services—improving outcomes for people with skin tumours including melanoma. 2006. https://www.nice.org.uk/nicemedia/live/10901/28907/28907.pdf
25 Scottish Intercollegiate Guidelines Network. Management of primary cutaneous squamous cell carcinoma. SIGN, 2014. http://www.sign.ac.uk/guidelines/fulltext/140/index.html.
26 Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013;347:f6153. doi:10.1136/bmj.f6153 pmid:24191270.
27 Mohs FE. Chemosurgery: microscopically controlled surgery for skin cancer. Charles C Thomas, 1978.
28 Robins P, Dzubow LM, Rigel DS. Squamous-cell carcinoma treated by Mohs’ surgery: an experience with 414 cases in a period of 15 years. J Dermatol Surg Oncol 1981;7:800-1.doi:10.1111/j.1524-4725.1981.tb00168.x pmid:7298979.
 29 Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion. J Am Acad Dermatol 2005;53:261-6. doi:10.1016/j.jaad.2005.03.048 pmid:16021121.
30 Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001;137:459-63.pmid:11295926.
31 Moloney FJ, Kelly PO, Kay EW, Conlon P, Murphy GM. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004;30:674-8.pmid:15061854.
32 Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012;106:811-5. doi:10.1002/jso.23155 pmid:22592943.
33 Jennings L, Schmults CD. Management of high-risk cutaneous squamous cell carcinoma. J Clin Aesthet Dermatol 2010;3:39-48.pmid:20725546.
34 Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in  atients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000;136:1524-30. doi:10.1001/archderm.136.12.1524 pmid:11115165.

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021